4.7 Meeting Abstract

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+operable breast cancer: 5-year outcomes of NSABP protocol B-41.

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 34, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2016.34.15_suppl.501

Keywords

-

Categories

Funding

  1. GlaxoSmithKline

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available